WHITEHAWK THERAPEUTICS INC (WHWK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.17+2.26%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · WHWK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -61.1% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 44.2% |
Growth built into the price is above our model estimate.
The price assumes 105.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
WHWK — President transition
Dated 2026-09-10
Director — Vijay Iyengar, M.D.: The filing discloses the appointment of a new non-employee director to a newly created board seat, which is a routine governance action rather than an executive departure.
Why it matters: The runway gives Whitehawk time to run trials and build its pipeline without needing new funding soon.
Worry ifA later company update keeps the cash runway at least into the second half of 2028.
Less concerning ifThe company cuts its runway estimate to before 2H 2028 or says it needs new funding sooner.
Why it matters: IND filings would show that the option is turning into new clinical programs.
Supportive ifWhitehawk files IND applications for at least two new ADC programs within 12 to 24 months of May 21, 2026.
Worry ifNo new ADC IND is filed by May 2028, or the company reports a delay to its stated plan.
Why it matters: The planned start is a test of whether Whitehawk can move its third ADC into human trials on time.
Supportive ifThe company confirms the HWK-206 Phase 1 trial started by September 30, 2026.
Worry ifThe trial has not started by the Q3 end, or the company reports a delay.
Why it matters: Early safety and tumor response data will test whether these ADCs can help patients.
Watch forThe company reports early data in 1H 2027. Look for signs of tumor response and no new major safety concern.
Also watch forData show no tumor response at tested doses, a major safety concern, or a delay past 1H 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$233 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $590 loss on $10,000 · 5.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,333 loss on $10,000 · 43.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.